Tinoridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tinoridine
Accession Number
DB13001
Type
Small Molecule
Groups
Investigational
Description

Tinoridine is under investigation in clinical trial NCT01224756 (Efficacy of Tinoridine in Treating Pain and Inflammation in Adults).

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tinoridine hydrochloride05IIB89IVA25913-34-2LMAQHEGFQZGATE-UHFFFAOYSA-N
Categories
UNII
C9Z9ICZ7YR
CAS number
24237-54-5
Weight
Average: 316.42
Monoisotopic: 316.124549066
Chemical Formula
C17H20N2O2S
InChI Key
PFENFDGYVLAFBR-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O2S/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12/h3-7H,2,8-11,18H2,1H3
IUPAC Name
ethyl 2-amino-6-benzyl-4H,5H,6H,7H-thieno[2,3-c]pyridine-3-carboxylate
SMILES
CCOC(=O)C1=C(N)SC2=C1CCN(CC1=CC=CC=C1)C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tinoridine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tinoridine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tinoridine is combined with 5-androstenedione.Experimental, Illicit
AbciximabTinoridine may increase the anticoagulant activities of Abciximab.Approved
AcebutololTinoridine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tinoridine.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tinoridine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTinoridine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tinoridine.Approved, Vet Approved
AclarubicinTinoridine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tinoridine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTinoridine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alendronic acid.Approved
AliskirenTinoridine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alminoprofen.Experimental
AlprenololTinoridine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tinoridine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Amcinonide.Approved
AmikacinTinoridine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideTinoridine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinTinoridine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodTinoridine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tinoridine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tinoridine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tinoridine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Tinoridine.Investigational
AnnamycinTinoridine may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tinoridine.Approved, Investigational
Antithrombin III humanTinoridine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanTinoridine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Tinoridine.Investigational
ApramycinTinoridine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tinoridine.Approved, Investigational
ArbekacinTinoridine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTinoridine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTinoridine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololTinoridine may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Atamestane.Investigational
AtenololTinoridine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tinoridine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tinoridine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Tinoridine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tinoridine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Tinoridine.Investigational
BalsalazideTinoridine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminTinoridine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTinoridine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTinoridine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tinoridine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tinoridine.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tinoridine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Betamethasone.Approved, Vet Approved
BetaxololTinoridine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tinoridine.Approved, Investigational
BevantololTinoridine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tinoridine.Approved, Investigational
BisoprololTinoridine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTinoridine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTinoridine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tinoridine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Tinoridine.Investigational
BucindololTinoridine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bufexamac.Approved, Experimental
BufuralolTinoridine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Tinoridine.Approved
BupranololTinoridine may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tinoridine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tinoridine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tinoridine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tinoridine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tinoridine.Approved, Vet Approved, Withdrawn
CarteololTinoridine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTinoridine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tinoridine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Celecoxib.Approved, Investigational
CeliprololTinoridine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinTinoridine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tinoridine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tinoridine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tinoridine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tinoridine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cilazapril.Approved
CinoxacinTinoridine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTinoridine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Tinoridine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tinoridine.Vet Approved
CloranololTinoridine may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tinoridine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Tinoridine.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tinoridine.Experimental
CyclosporineTinoridine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTinoridine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTinoridine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTinoridine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanTinoridine may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinTinoridine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tinoridine is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tinoridine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Delapril.Experimental
DesirudinTinoridine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tinoridine.Approved, Investigational
DextranTinoridine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Tinoridine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tinoridine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tinoridine may increase the anticoagulant activities of Dextran 75.Approved
DibekacinTinoridine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Tinoridine is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tinoridine.Approved, Vet Approved
DicoumarolTinoridine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinoridine.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tinoridine.Approved
DihydrostreptomycinTinoridine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tinoridine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tinoridine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tinoridine.Approved
DoxorubicinTinoridine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTinoridine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Tinoridine.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Tinoridine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Tinoridine.Investigational
Edetic AcidTinoridine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTinoridine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Tinoridine is combined with Enalaprilat.Approved
EnoxacinTinoridine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTinoridine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tinoridine.Experimental
EpanololTinoridine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Tinoridine.Approved
EpirubicinTinoridine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Tinoridine.Experimental
EplerenoneTinoridine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tinoridine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tinoridine.Approved
EquileninThe risk or severity of adverse effects can be increased when Tinoridine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tinoridine is combined with Equilin.Approved
EsmololTinoridine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tinoridine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tinoridine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTinoridine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Tinoridine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Tinoridine.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tinoridine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tinoridine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Tinoridine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tinoridine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tinoridine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Feprazone.Experimental
Ferulic acidTinoridine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tinoridine.Approved, Investigational
FleroxacinTinoridine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tinoridine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fludrocortisone.Approved, Investigational
FluindioneTinoridine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTinoridine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Tinoridine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tinoridine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tinoridine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tinoridine.Approved, Nutraceutical, Vet Approved
FondaparinuxTinoridine may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumTinoridine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tinoridine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fosinopril.Approved
FramycetinTinoridine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Tinoridine.Approved, Vet Approved
GabexateTinoridine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTinoridine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTinoridine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tinoridine.Approved, Withdrawn
GemifloxacinTinoridine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTinoridine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTinoridine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATinoridine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Tinoridine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTinoridine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Tinoridine is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Tinoridine is combined with HE3286.Investigational
HeparinTinoridine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Tinoridine.Investigational
HydralazineTinoridine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tinoridine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tinoridine.Approved, Investigational
Hygromycin BTinoridine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tinoridine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Tinoridine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tinoridine.Approved, Investigational
IdarubicinTinoridine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTinoridine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tinoridine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tinoridine.Approved
IndenololTinoridine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Tinoridine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tinoridine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Tinoridine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tinoridine.Approved, Investigational
IsepamicinTinoridine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tinoridine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tinoridine is combined with Istaroxime.Investigational
KanamycinTinoridine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Tinoridine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tinoridine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tinoridine.Approved
LabetalolTinoridine may decrease the antihypertensive activities of Labetalol.Approved
LandiololTinoridine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tinoridine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tinoridine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tinoridine.Approved, Investigational
LepirudinTinoridine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTinoridine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTinoridine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTinoridine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Tinoridine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Tinoridine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tinoridine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tinoridine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tinoridine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tinoridine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tinoridine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tinoridine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tinoridine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tinoridine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tinoridine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tinoridine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tinoridine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tinoridine.Approved
MelagatranTinoridine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tinoridine.Approved, Vet Approved
MepindololTinoridine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineTinoridine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tinoridine.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tinoridine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tinoridine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTinoridine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tinoridine.Approved
MetoprololTinoridine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTinoridine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinTinoridine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tinoridine.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tinoridine.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tinoridine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tinoridine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tinoridine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tinoridine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Nabumetone.Approved
NadololTinoridine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTinoridine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatTinoridine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tinoridine.Approved
Nalidixic AcidTinoridine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tinoridine.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Tinoridine is combined with NCX 1022.Investigational
NeamineTinoridine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTinoridine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTinoridine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTinoridine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tinoridine.Approved, Investigational
NetilmicinTinoridine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tinoridine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tinoridine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tinoridine.Investigational
NorfloxacinTinoridine may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tinoridine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tinoridine.Approved
OlsalazineTinoridine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Tinoridine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Tinoridine is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Tinoridine.Vet Approved
OtamixabanTinoridine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tinoridine.Approved
Oxolinic acidTinoridine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTinoridine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tinoridine.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Parecoxib.Approved
ParomomycinTinoridine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Parthenolide.Approved, Investigational
PazufloxacinTinoridine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTinoridine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTinoridine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTinoridine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateTinoridine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Perindopril.Approved
PhenindioneTinoridine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonTinoridine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tinoridine.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tinoridine.Approved, Investigational
PindololTinoridine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidTinoridine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTinoridine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tinoridine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tinoridine.Approved, Investigational
Piromidic acidTinoridine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tinoridine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorTinoridine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTinoridine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTinoridine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tinoridine.Approved
PractololTinoridine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tinoridine.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Tinoridine can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Tinoridine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Tinoridine.Approved, Investigational
PropranololTinoridine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tinoridine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tinoridine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tinoridine.Vet Approved
Protein CTinoridine may increase the anticoagulant activities of Protein C.Approved
Protein S humanTinoridine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTinoridine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTinoridine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tinoridine.Investigational
PuromycinTinoridine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tinoridine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tinoridine.Approved, Experimental, Investigational
ReviparinTinoridine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTinoridine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Risedronate.Approved, Investigational
RivaroxabanTinoridine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinTinoridine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTinoridine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTinoridine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tinoridine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tinoridine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tinoridine.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tinoridine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tinoridine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tinoridine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tinoridine.Approved, Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Tinoridine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tinoridine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tinoridine is combined with Serrapeptase.Investigational
SisomicinTinoridine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTinoridine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tinoridine.Approved
SotalolTinoridine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTinoridine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTinoridine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTinoridine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Spirapril.Approved
SpironolactoneTinoridine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tinoridine.Investigational
StreptomycinTinoridine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTinoridine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tinoridine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tinoridine.Approved, Investigational
SulodexideTinoridine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tinoridine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tinoridine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Suxibuzone.Experimental
TacrolimusTinoridine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tinoridine.Approved
TalinololTinoridine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tinoridine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tinoridine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tinoridine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tinoridine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tinoridine.Approved, Investigational
TemafloxacinTinoridine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tinoridine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Tinoridine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Tinoridine.Approved
TertatololTinoridine may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tinoridine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTinoridine may decrease the antihypertensive activities of Timolol.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tixocortol.Approved, Withdrawn
TobramycinTinoridine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Tinoridine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tinoridine.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Tinoridine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Tinoridine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tinoridine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tinoridine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tinoridine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTinoridine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tinoridine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tinoridine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Tinoridine.Investigational
TrovafloxacinTinoridine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTinoridine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tinoridine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Tinoridine is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinTinoridine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tinoridine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tinoridine.Approved
WarfarinTinoridine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranTinoridine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tinoridine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tinoridine.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Tinoridine is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tinoridine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tinoridine.Withdrawn
Zoptarelin doxorubicinTinoridine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTinoridine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5480
PubChem Substance
347829138
ChemSpider
5280
BindingDB
50304470
ChEBI
135353
ChEMBL
CHEMBL592943

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.021 mg/mLALOGPS
logP3.2ALOGPS
logP3.94ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)17.65ChemAxon
pKa (Strongest Basic)7.31ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity90.05 m3·mol-1ChemAxon
Polarizability34.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thienopyridines. These are heterocyclic compounds containing a thiophene ring fused to a pyridine ring. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thienopyridines
Sub Class
Not Available
Direct Parent
Thienopyridines
Alternative Parents
3,4,5-trisubstituted-2-aminothiophenes / Benzylamines / Phenylmethylamines / Thiophene carboxylic acids and derivatives / Aralkylamines / Heteroaromatic compounds / Vinylogous amides / Amino acids and derivatives / Carboxylic acid esters / Trialkylamines
show 7 more
Substituents
Thienopyridine / 3,4,5-trisubstituted-2-aminothiophene / Benzylamine / Phenylmethylamine / Thiophene carboxylic acid or derivatives / Aralkylamine / Monocyclic benzene moiety / 2-aminothiophene / Benzenoid / Heteroaromatic compound
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:59 / Updated on March 02, 2018 05:33